Pfizer's Abandoned Merger with Bristol Myers Stokes Fears of a Post-Pandemic Slump in Big Pharma Deals In a surprise move, pharmaceutical giant Pfizer has scrapped its planned merger with US rival Bristol Myers Squibb, a deal that would have marked a major return to the big pharma mergers that dominated the industry landscape before the pandemic. The abandoned tie-up, worth a staggering $70 billion, would have been one of the largest in the sector in years, sparking concerns about the future of consolidation in the industry. Analysts are now left wondering if the collapse of the deal signals a broader slowdown in the pace of mergers and acquisitions in the pharmaceutical sector, or if Pfizer is simply taking a cautious approach in a rapidly changing market. With the global healthcare landscape continuing to evolve, the implications of this deal's demise are set to send shockwaves through the industry.
Tie-up with US rival Bristol Myers would have marked return to big pharma mergers
